MoneyWorks4Me

Sai Life Sciences informs about allotment of equity shares under ESOP

01 Sep 2026 Evaluate

Sai Life Sciences has informed that, pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations the Board of Directors by the way of Circular Resolution on 01st September 2026, had approved the allotment of 14,600 and 66,000 fully paid-up equity shares having a face value of ?1 each upon exercise of options granted under ESOP 2008 and MESOP 2018 respectively. Consequent to aforesaid allotment the issued, subscribed, and paid-up equity share capital of the Company has increased from ?21,23,13,617 to ?21,23,94,216. The details required under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (‘SEBI ESOP Regulations 2021’) are enclosed as Annexure-A.

The above information is a part of company’s filings submitted to BSE.

Sai Life Sciences Share Price

1562.00 43.10 (2.84%)
02-Sep-2026 09:49 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1936.75
Dr. Reddys Labs. 1165.60
Cipla 1405.05
Lupin 2144.15
Zydus Lifesciences 1161.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: